BRIEF-Edge Therapeutics says received FDA fast-track designation for drug to treat subarachnoid hemorrhage

* Expects to begin enrollment in mid-2016, a pivotal phase 3

multi-center, multi-national, randomized, double-blind,

placebo-controlled, parallel-group study

Read more